Susceptibility of 100 strains of Stenotrophomonas maltophilia to three beta-lactams and five beta-lactam-beta-lactamase inhibitor combinations | Zendy

Marylin LecsöBornet | Zendy

Open Access

Susceptibility of 100 strains of Stenotrophomonas maltophilia to three beta-lactams and five beta-lactam-beta-lactamase inhibitor combinations

Author(s) -

Marylin LecsöBornet

Publication year - 1997

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/40.5.717

Subject(s) - ticarcillin , clavulanic acid , sulbactam , piperacillin , stenotrophomonas maltophilia , microbiology and biotechnology , piperacillin/tazobactam , ceftazidime , tazobactam , beta lactamase inhibitors , beta lactamase , stenotrophomonas , medicine , antibiotics , chemistry , biology , imipenem , amoxicillin , bacteria , pseudomonas , antibiotic resistance , pseudomonas aeruginosa , biochemistry , escherichia coli , genetics , gene

One hundred clinical strains of Stenotrophomonas maltophilia were investigated for their susceptibility to ticarcillin, piperacillin, ceftazidime and five combinations with beta-lactamase inhibitors (clavulanic acid, tazocillin or sulbactam) at three concentrations; 26% of the strains were susceptible to ticarcillin, 23% to ceftazidime and 12% to piperacillin. Eighty-two percent of the strains were susceptible to ticarcillin/clavulanic acid. In most cases, no synergy was observed with tazobactam or sulbactam. For eight ticarcillin-susceptible strains, antagonism was observed between ticarcillin and clavulanic acid.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research